{"id":28204,"date":"2025-12-23T04:25:50","date_gmt":"2025-12-23T08:25:50","guid":{"rendered":"https:\/\/www.red94.net\/news\/cai-stock-soars-16-this-month-as-caris-life-sciences-crushes-earnings-and-wall-street-sees-major-upside-ahead\/"},"modified":"2025-12-23T04:25:50","modified_gmt":"2025-12-23T08:25:50","slug":"30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str","status":"publish","type":"post","link":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/","title":{"rendered":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead"},"content":{"rendered":"

Caris Life Sciences (CAI) has delivered impressive momentum this month, with shares climbing 16%<\/b> in December as Wall Street analysts maintain strong conviction on the precision medicine leader. The biotech giant delivered record third-quarter results in November, and investors are positioning ahead of what could be a pivotal 2026 for the AI-driven molecular profiling company.<\/p>\n

\n

\ud83d\udd25 Quick Facts<\/h3>\n
    \n
  • CAI stock surged 16% in December 2025<\/b> through December 23 as investors recognize strong earnings momentum<\/li>\n
  • Q3 2025 revenue hit $216.8 million<\/b>, up 113.4% year-over-year with record clinical volumes at 50,763 cases<\/b><\/li>\n
  • Caris raised full-year 2025 revenue guidance to $720-$730 million<\/b>, representing 75-77% growth above prior year<\/li>\n
  • Wall Street consensus targets average $34.71 per share<\/b>, implying potential $38 upside from current levels per analyst ratings<\/li>\n<\/ul>\n<\/div>\n

    Record Quarter Validates Biotech Growth Strategy<\/h2>\n

    Caris Life Sciences demonstrated exceptional operational execution in the third quarter of 2025, posting $216.8 million in total revenue<\/b> compared to $101.6 million in the year-ago quarter. The 113.4% year-over-year growth<\/b> was driven primarily by the company’s core molecular profiling services business, which grew 121.3% to $207.6 million.<\/p>\n

    The company achieved a notable inflection point: positive net income of $24.3 million<\/b> in Q3 2025, compared to a net loss of $67.7 million in Q3 2024. This turnaround reflects the operating leverage in Caris’s precision medicine platform as the company scales its AI-powered diagnostic solutions across oncology and other therapeutic areas.<\/p>\n

    Clinical case volume reached 50,763 therapy selection cases<\/b>, up just 18.2% year-over-year, but average selling prices expanded 87.2% to $4,089 per case. This pricing power demonstrates strong reimbursement momentum and customer willingness to pay for Caris’s comprehensive molecular insights.<\/p>\n

    Margin Expansion and Cash Generation Accelerate Profitability Path<\/h2>\n

    Gross margin expanded dramatically to 68%<\/b> in Q3 2025 from just 43.7% a year earlier, an improvement of 2,432 basis points. This expansion reflects the inherent scalability of molecular profiling when combined with Caris’s advanced AI and machine learning infrastructure.<\/p>\n

    The company also achieved positive Adjusted EBITDA of $51.2 million<\/b> and positive free cash flow of $55.3 million<\/b> in the quarter. Operating cash flow reached $62.4 million<\/b>, a dramatic swing from negative $69.4 million in Q3 2024. The company ended September with $759 million in cash<\/b>, providing substantial runway for product development and potential M&A.<\/p>\n

    Management projected 2025 full-year revenue guidance of $720-$730 million<\/b>, at the high end of previous expectations. This guidance implies the fourth quarter will contribute approximately $200-$210 million, suggesting the strong momentum continues into year-end.<\/p>\n

    What Wall Street Says About CAI’s Valuation Opportunity<\/h2>\n\n\n\n\n\n\n\n\n
    Metric<\/td>\nValue<\/td>\n<\/tr>\n
    Average Price Target (7 Analysts)<\/td>\n$34.71<\/b><\/td>\n<\/tr>\n
    Current Price (Dec 23, 2025)<\/td>\n$28.46<\/b><\/td>\n<\/tr>\n
    Upside from Current Levels<\/td>\n21.96%<\/b> to consensus target<\/td>\n<\/tr>\n
    Highest Price Target<\/td>\n$42<\/b> (Citigroup, +47.6%)<\/td>\n<\/tr>\n
    Consensus Rating<\/td>\nStrong Buy<\/b> (6 of 7 analysts)<\/td>\n<\/tr>\n
    Recent Canaccord Rating<\/td>\nRaised to $30 on Dec 22, 2025<\/td>\n<\/tr>\n<\/table>\n

    Analyst sentiment shifted materially in December<\/b> after Caris demonstrated profitability at scale. Canaccord Genuity raised its price target to $30<\/b> on December 22, 2025, citing the company’s ability to achieve positive net income while continuing to grow revenue at 75%+ rates. Guggenheim maintains a Strong Buy with $36 target<\/b>, while Evercore ISI Group targets $40<\/b> and Citigroup has the street high at $42<\/b>.<\/p>\n

    The consensus view among Wall Street professionals is that CAI’s precision medicine platform addresses a secular growth opportunity in oncology diagnostics worth tens of billions annually. As reimbursement expands and clinical adoption accelerates, analysts expect CAI to become accretive to earnings in 2026.<\/p>\n

    Infrastructure and Pipeline Position CAI for Sustained Growth<\/h2>\n

    Caris operates one of healthcare’s largest clinico-genomic databases, with 959,000 total molecular profiles<\/b> accumulated by September 2025. The company processed more than 577,000 Whole Exome and 628,000 Whole Transcriptome sequencing profiles<\/b>, representing years of accumulated clinical and genomic data that train its proprietary AI algorithms.<\/p>\n

    The company published two validation studies in Q3 demonstrating the clinical utility of its molecular profiling approach in breast cancer therapy selection. Management highlighted early progress on next-generation products including MI Cancer Seek for early cancer detection<\/b> and MRD (minimal residual disease) monitoring solutions<\/b>, which could expand TAM significantly beyond current therapy selection applications.<\/p>\n

    Revenue guidance for 2026 suggests continued acceleration to approximately $990 million<\/b>, implying 35% growth. If achieved, this would position CAI as a multi-billion dollar precision medicine player by 2027-2028.<\/p>\n

    Can Caris Life Sciences Sustain This Momentum Through 2026?<\/h2>\n

    The key question for investors is whether Caris can continue executing at this pace<\/b> as the company scales. With $759 million in cash and improving operating cash flow, the company has substantial flexibility to invest in sales infrastructure, R&D, and potential strategic acquisitions without external financing.<\/p>\n

    Execution risks include healthcare reimbursement policy changes<\/b>, competitive pressure from larger diagnostics players<\/b>, and the ability to commercialize next-generation products<\/b> like early detection solutions. However, the company’s proprietary data moat and clinical validation give it meaningful advantages in the precision medicine space.<\/p>\n

    The 16% December rally<\/b> reflects growing institutional recognition that Caris has turned an inflection point from pre-revenue biotech into a cash-generating precision medicine powerhouse. With Wall Street targets suggesting 22-48% upside from current levels, the street appears to be positioning for accelerating growth and margin expansion in 2026.<\/p>\n

    \n“These results reflect the core strength of our business and our continued progress toward delivering the next generation of personalized solutions through our exciting pipeline in MRD and early detection.”\n<\/p><\/blockquote>\n

    \u2014 David D. Halbert<\/b>, Founder, Chairman and CEO of Caris Life Sciences<\/p>\n

    Sources<\/h3>\n
      \n
    • PR Newswire<\/b> – Caris Life Sciences Q3 2025 earnings release, November 5, 2025<\/li>\n
    • StockAnalysis.com<\/b> – CAI stock forecast and analyst ratings, December 2025<\/li>\n
    • Yahoo Finance<\/b> – Real-time CAI stock quotes and recent price movement<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":23,"featured_media":28203,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"schema_org_data":"{\"@context\":\"https:\/\/schema.org\",\"@graph\":[]}","_extracted_celebrities":"","_extracted_movies":"","_extracted_places":"","_extracted_videos":"","_last_enrichment_date":"2025-12-23 04:26:22","footnotes":""},"categories":[391],"tags":[],"class_list":["post-28204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-finance","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"yoast_head":"\nCAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead\" \/>\n<meta property=\"og:description\" content=\"…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\" \/>\n<meta property=\"og:site_name\" content=\"Red94\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-23T08:25:50+00:00\" \/>\n<meta name=\"author\" content=\"Patrick Graham\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrick Graham\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\"},\"author\":{\"name\":\"Patrick Graham\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\"},\"headline\":\"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead\",\"datePublished\":\"2025-12-23T08:25:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\"},\"wordCount\":880,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.red94.net\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png\",\"articleSection\":[\"Business & Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\",\"url\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\",\"name\":\"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead\",\"isPartOf\":{\"@id\":\"https:\/\/www.red94.net\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png\",\"datePublished\":\"2025-12-23T08:25:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png\",\"width\":1200,\"height\":678,\"caption\":\"CAI stock soars 16% this month as biotech giant eyes $725M revenue target, Wall Street sees $38 upside ahead\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.red94.net\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entertainment\",\"item\":\"https:\/\/www.red94.net\/news\/entertainment\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.red94.net\/news\/#website\",\"url\":\"https:\/\/www.red94.net\/news\/\",\"name\":\"Red94\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.red94.net\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.red94.net\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.red94.net\/news\/#organization\",\"name\":\"Red94\",\"url\":\"https:\/\/www.red94.net\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"width\":289,\"height\":90,\"caption\":\"Red94\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\",\"name\":\"Patrick Graham\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"caption\":\"Patrick Graham\"},\"description\":\"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.\",\"url\":\"https:\/\/www.red94.net\/news\/author\/patrick-graham\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/","og_locale":"en_US","og_type":"article","og_title":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead","og_description":"…","og_url":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/","og_site_name":"Red94","article_published_time":"2025-12-23T08:25:50+00:00","author":"Patrick Graham","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrick Graham","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#article","isPartOf":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/"},"author":{"name":"Patrick Graham","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9"},"headline":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead","datePublished":"2025-12-23T08:25:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/"},"wordCount":880,"commentCount":0,"publisher":{"@id":"https:\/\/www.red94.net\/news\/#organization"},"image":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage"},"thumbnailUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png","articleSection":["Business & Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/","url":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/","name":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead","isPartOf":{"@id":"https:\/\/www.red94.net\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage"},"image":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage"},"thumbnailUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png","datePublished":"2025-12-23T08:25:50+00:00","breadcrumb":{"@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#primaryimage","url":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/84494-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str.jpg-scaled.png","width":1200,"height":678,"caption":"CAI stock soars 16% this month as biotech giant eyes $725M revenue target, Wall Street sees $38 upside ahead"},{"@type":"BreadcrumbList","@id":"https:\/\/www.red94.net\/news\/30299-cai-stock-soars-16-this-month-as-biotech-giant-eyes-725m-revenue-target-wall-str\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.red94.net\/news\/"},{"@type":"ListItem","position":2,"name":"Entertainment","item":"https:\/\/www.red94.net\/news\/entertainment\/"},{"@type":"ListItem","position":3,"name":"CAI stock soars 16% this month as Caris Life Sciences crushes earnings and Wall Street sees major upside ahead"}]},{"@type":"WebSite","@id":"https:\/\/www.red94.net\/news\/#website","url":"https:\/\/www.red94.net\/news\/","name":"Red94","description":"","publisher":{"@id":"https:\/\/www.red94.net\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.red94.net\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.red94.net\/news\/#organization","name":"Red94","url":"https:\/\/www.red94.net\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","width":289,"height":90,"caption":"Red94"},"image":{"@id":"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9","name":"Patrick Graham","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/image\/","url":"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","caption":"Patrick Graham"},"description":"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.","url":"https:\/\/www.red94.net\/news\/author\/patrick-graham\/"}]}},"views":27,"_links":{"self":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts\/28204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/comments?post=28204"}],"version-history":[{"count":0,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts\/28204\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/media\/28203"}],"wp:attachment":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/media?parent=28204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/categories?post=28204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/tags?post=28204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}